Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CloFluBu versus BuCyMel conditioning before allogeneic stem cell transplantation in children with AML
2021-003282-36Phase 3Active
- Sponsor
- Region Västra Götaland
- Start
- Sep 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of busulfan, clofarabine, fludarabine, cyclophosphamide and melphalan in acute myeloid leukemia (AML) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: 2-year graft-versus-host disease- and relapse-free survival. Started Sep 2021; status: active.
02
Drugs
busulfanclofarabinefludarabinecyclophosphamidemelphalan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-003282-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003282-36.